Keywords

AIDS, emtricitabine/tenofovir disoproxil fumarate, HIV, preexposure prophylaxis therapy, prevention, sexually transmitted infection

Authors

1. Blackwell, Christopher W. PhD, ARNP, ANP-BC, CNE, AGACNP-BC

Abstract

Abstract: The HIV antiretroviral drug emtricitabine/tenofovir disoproxil fumarate (Truvada) was recently approved as preexposure prophylaxis (PrEP) therapy for adults at high risk for sexually acquired HIV infection. This article reviews the data supporting the efficacy of PrEP, and provides other relevant data regarding the implementation of PrEP.